<DOC>
	<DOC>NCT03040206</DOC>
	<brief_summary>This study is to investigate the prognostic significance of enhanced International Prognostic Index (NCCN-IPI) and post-treatment PET results in patients with newly diagnosed nodal peripheral T-cell lymphoma (PTCL), and establish a risk stratification model for nodal PTCL patients.</brief_summary>
	<brief_title>Risk Stratification of Nodal PTCL</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, T-Cell</mesh_term>
	<mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
	<mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<criteria>Patients diagnosed with nodal PTCLs (PTCL, NOS; Angioimmunblastic Tcell lymphoma; anaplastic large cell lymphoma [ALCL], anaplastic lymphoma kinase [ALK]negative) Patients diagnosed with between January 1, 2004 and April 30, 2016 initially treated with curative intent Patients with standard 18Ffluorodeoxyglucose (FDG) PET or PETCT data at the time of diagnosis and at the end of primary treatment Patients diagnosed with extranodal PTCLs, including followings (extranodal NK/Tcell lymphoma, nasal type; enteropathyassociated Tcell lymphoma; hepatosplenic Tcell lymphoma; subcutaneous panniculitislike Tcell lymphoma; EBVpositive Tcell lymphoproliferative childhood disorders, and primary cutaneous lymphomas) Patients with ALCLALK+ Patients who do not have 18FFDG PET or PETCT data either at diagnosis or at the end of treatment available for review</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>